Compare BioNano Genomics Inc (BNGO) vs MONDELEZ INTERNATIONAL INC Common Stock (MDLZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs MONDELEZ INTERNATIONAL INC Common Stock — how do they compare? BioNano Genomics Inc trades at $1.18 (market cap $13.20M), while MONDELEZ INTERNATIONAL INC Common Stock trades at $58.78 (market cap $75.48B). The key difference: MONDELEZ INTERNATIONAL INC Common Stock is far larger — about 5718.2× BioNano Genomics Inc's market cap, and MONDELEZ INTERNATIONAL INC Common Stock pays a 3.4% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| BNGO | MDLZ | |
|---|---|---|
Market Cap | $13.20M | $75.48B |
Sector | Health | Consumer Staples |
52-Week High | $4.92 | $70.75 |
52-Week Low | $1.09 | $51.51 |
Enterprise Value | $15.81M | $95.58B |
Dividend Yield | — | 3.4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bionano Genomics (BNGO) trades at $1.17, down 2.5% today, but maintains a bullish technical signal with strong moving average support. The company shows improving fundamentals with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable with a -109.95% net margin. Recent positive developments include debt retirement and growing adoption of optical genome mapping technology.
BNGO presents a high-risk, high-reward opportunity with analyst consensus leaning bullish (57% buy ratings). The stock trades at attractive valuation multiples (P/S 0.31, P/B 0.36) but faces execution risks in achieving profitability. Key catalysts include continued technology adoption and potential margin improvement, while persistent losses and competitive pressures remain concerns.
MDLZ trades at $59.86, up 1.75% today, with a neutral technical signal and bullish moving averages. Revenue grew to $38.54B in 2025, though net income fell to $2.45B. The company maintains strong brand innovation with recent product launches and a new CFO appointment. Analysts show strong buy sentiment with a $68.00 consensus target, implying 13.6% upside.
Outlook remains positive driven by consistent earnings beats and brand strength, but risks include margin pressure from input costs and competitive headwinds. The stock offers a balanced opportunity for growth investors seeking stable consumer staples exposure with dividend income.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About MONDELEZ INTERNATIONAL INC Common Stock
Mondelez has operated as an independent organization since its split from the former Kraft Foods North American grocery business in October 2012. The firm is a leading player in the global snack arena with a presence in the biscuit (47% of sales), chocolate (32%), gum/candy (10%), beverage (4%), and cheese and grocery (7%) aisles. Mondelez's portfolio includes well-known brands like Oreo, Chips Ahoy, Halls, Trident, and Cadbury, among others. The firm derives around one third of revenue from developing markets, nearly 40% from Europe, and the remainder from North America.
Read more on MDLZ →
